Publications in collaboration with researchers from Hospital del Bierzo (20)

2021

  1. The Experience With Health Care of Patients With Inflammatory Arthritis: A Cross-sectional Survey Using the Instrument to Evaluate the Experience of Patients With Chronic Diseases

    Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, Vol. 27, Núm. 1, pp. 25-30

2015

  1. Anti-TNF-α therapy reduces endothelial cell activation in non-diabetic ankylosing spondylitis patients

    Rheumatology International, Vol. 35, Núm. 12, pp. 2069-2078

  2. Variability in the prescription of non-biologic disease-modifying antirheumatic drugs for the treatment of spondyloarthritis in Spain

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 633-640

2014

  1. Adipokines, biomarkers of endothelial activation, and metabolic syndrome in patients with ankylosing spondylitis

    BioMed Research International, Vol. 2014

  2. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients

    Annals of the Rheumatic Diseases

  3. Correlation between two biomarkers of atherosclerosis, osteopontin and angiopoietin-2, in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 231-236

  4. Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 218-224

  5. IGF-1 and ADMA Levels Are Inversely Correlated in Nondiabetic Ankylosing Spondylitis Patients Undergoing Anti-TNF-Alpha Therapy

    BioMed Research International, Vol. 2014

  6. Osteoprotegerin correlates with disease activity and endothelial activation in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 5, pp. 640-646

  7. Patients with ankylosing spondylitis and low disease activity because of anti-TNF-Alpha therapy have higher TRAIL levels than controls: A potential compensatory effect

    Mediators of Inflammation, Vol. 2014

2013

  1. Adiponectin and resistin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 3, pp. 365-371

  2. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients

    Annals of the Rheumatic Diseases

  3. Apelin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 4, pp. 532-537

  4. Asymmetric dimethylarginine serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 5, pp. 749-755

  5. Correlation between insulin resistance and serum ghrelin in non-diabetic ankylosing spondylitis patients undergoing anti-TNF-α therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 6, pp. 913-918

  6. Leptin and visfatin serum levels in non-diabetic ankylosing spondylitis patients undergoing TNF-α antagonist therapy

    Clinical and Experimental Rheumatology, Vol. 31, Núm. 4, pp. 538-545

2012

  1. TNF-alpha antagonist therapy improves insulin sensitivity: In non-diabetic ankylosing spondylitis patients

    Clinical and Experimental Rheumatology, Vol. 30, Núm. 6, pp. 850-855

2008

  1. Reacciones adversas relacionadas con la administración de inhibidores del TNF. Análisis de un registro de terapias biológicas

    Reumatologia Clinica, Vol. 4, Núm. 3, pp. 90-95

2007

  1. Registro Español de Acontecimientos Adversos de Terapias Biológicas en Enfermedades Reumáticas (BIOBADASER): Informe de la situación, 26 de enero de 2006

    Reumatologia Clinica, Vol. 3, Núm. 1, pp. 4-20

2006

  1. Switching TNF antagonists in patients with chronic arthritis: An observational study of 488 patients over a four-year period

    Arthritis Research and Therapy, Vol. 8, Núm. 1